Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Glenwood G Gum"'
Publikováno v:
Clinical Ophthalmology (Auckland, N.Z.)
Roy S Rubinfeld,1 Glenwood G Gum,2 Jonathan H Talamo,1,3 Edward C Parsons1 1CXL Ophthalmics, LLC, Encinitas, CA, USA; 2Absorption Systems California, LLC, San Diego, CA, USA; 3Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical Sc
Publikováno v:
International Journal of Retina and Vitreous
International Journal of Retina and Vitreous, Vol 5, Iss 1, Pp 1-1 (2019)
International Journal of Retina and Vitreous, Vol 5, Iss 1, Pp 1-1 (2019)
Background To evaluate the efficacy of selective episcleral delivery of celecoxib formulated in a sustained-release episcleral exoplant on a model of retinal and choroidal neovascularization induced in rabbits by subretinal injection of matrigel comb
Publikováno v:
International Journal of Retina and Vitreous
International Journal of Retina and Vitreous, Vol 4, Iss 1, Pp 1-8 (2018)
International Journal of Retina and Vitreous, Vol 4, Iss 1, Pp 1-8 (2018)
Background To evaluate the efficacy of selective episcleral delivery of celecoxib formulated in a sustained-release episcleral exoplant on a model of retinal and choroidal neovascularization induced in rabbits by subretinal injection of matrigel comb
Publikováno v:
Journal of cataract and refractive surgery. 44(2)
Purpose To compare the corneal stromal riboflavin concentration and distribution using 2 transepithelial corneal crosslinking (CXL) systems. Setting Absorption Systems, San Diego, California, USA. Design Experimental study. Methods The stromal ribofl
Publikováno v:
Investigative ophthalmologyvisual science. 58(11)
Purpose The purpose of this study was to determine the safety of topical ocular administration of a cross-linked, modified hyaluronic acid (xCMHA-S) hydrogel, and its effectiveness in accelerating repair and closure of acute and nonhealing corneal ul
Publikováno v:
Journal of the American Association for Laboratory Animal Science : JAALAS. 52(4)
To determine the effects of intravenous and intramuscular xylazine–ketamine on intraocular pressure (IOP) in laboratory rabbits, 10 New Zealand white rabbits received xylazine (0.46 mg/kg) and ketamine (1.5 mg/kg) intravenously whereas another 10 r
Publikováno v:
Journal of ocular pharmacology. 7(2)
Topical instillations of 1.0, 10, and 20 micrograms/50 microliters of prostaglandin PGA2, 0.5 and 1.0 microgram/50 microliters of PGA2 isopropyl ester, and 0.5, 1.0, 5.0 and 10.0 micrograms/50 microliters of PGF2 alpha isopropyl ester were evaluated
Autor:
Glenwood G. Gum
Publikováno v:
Veterinary Clinics of North America: Small Animal Practice. 10:437-454
Autor:
Naageshwaran V; University of Eastern Finland, School of Pharmacy, Yliopistonranta 1, 70210 Kuopio, Finland; Pharmaron, 7901 Vickers Street, San Diego, CA 92111, USA; 436 Creamery Way, Exton, PA, USA., Bigonne H; University of Eastern Finland, School of Pharmacy, Yliopistonranta 1, 70210 Kuopio, Finland., Gum G; Pharmaron, 7901 Vickers Street, San Diego, CA 92111, USA., Malla S; Pharmaron, 7901 Vickers Street, San Diego, CA 92111, USA; 436 Creamery Way, Exton, PA, USA., Del Sol C; Biostudy Solutions, LLC, 4008 Caesar Court, Wilmington, NC 28405, USA., Bon C; Biostudy Solutions, LLC, 4008 Caesar Court, Wilmington, NC 28405, USA., Xu X; Division of Product Quality Research, Office of Testing and Research, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA., Vo A; Division of Product Quality Research, Office of Testing and Research, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA., Smith W; Division of Product Quality Research, Office of Testing and Research, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA., O'Reilly Beringhs A; Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA., Kozak D; Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA., Tan ML; Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA., Babiskin A; Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA., Urtti A; University of Eastern Finland, School of Pharmacy, Yliopistonranta 1, 70210 Kuopio, Finland; University of Helsinki, Faculty of Pharmacy, Viikinkaari 5 E, 00790 Helsinki, Finland., Del Amo EM; University of Eastern Finland, School of Pharmacy, Yliopistonranta 1, 70210 Kuopio, Finland. Electronic address: eva.delamo@uef.fi., Ranta VP; University of Eastern Finland, School of Pharmacy, Yliopistonranta 1, 70210 Kuopio, Finland.
Publikováno v:
International journal of pharmaceutics [Int J Pharm] 2023 Jul 25; Vol. 642, pp. 123183. Date of Electronic Publication: 2023 Jun 25.
Autor:
Brooks D; University of Florida, Gainesville, Florida, USA.; Brookseyes LLC, Alachua Florida, Florida, USA., Linares-Alba MA; Laboratorio Santgar Fórmulas Magistrales de México SA de CV, Mexico City, Mexico., Garcia-Santisteban R; Hospital Veterinario Oftalvet, Mexico City, Mexico., Xie E; Absorptions Systems California, LLC (ASC), San Diego, California, USA., Gum G; Absorptions Systems California, LLC (ASC), San Diego, California, USA., Manza LL; Absorptions Systems California, LLC (ASC), San Diego, California, USA., Servitje-Azcarraga L; School of Medicine, Universidad Panamericana, Mexico City, Mexico., Santisteban DG; Laboratorio Santgar Fórmulas Magistrales de México SA de CV, Mexico City, Mexico., García-Sánchez GA; Laboratorio Santgar Fórmulas Magistrales de México SA de CV, Mexico City, Mexico.
Publikováno v:
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics [J Ocul Pharmacol Ther] 2022 Jul-Aug; Vol. 38 (6), pp. 424-432. Date of Electronic Publication: 2022 Jul 14.